{"id":8789,"date":"2023-10-30T17:07:28","date_gmt":"2023-10-30T14:07:28","guid":{"rendered":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/"},"modified":"2023-10-30T17:07:28","modified_gmt":"2023-10-30T14:07:28","slug":"kuna-dawa-ambayo-itaondoa-unene","status":"publish","type":"post","link":"https:\/\/urbancare.clinic\/sw\/kuna-dawa-ambayo-itaondoa-unene\/","title":{"rendered":"Je, Kuna Dawa Ya Kuondoa Unene?"},"content":{"rendered":"
<\/div>\n

Kulingana na Shirika la Afya Ulimwenguni (WHO), uzito kupita kiasi na unene kupita kiasi hufafanuliwa kuwa \u201cmrundikano wa mafuta kupita kiasi usio wa kawaida au kupita kiasi unaoleta hatari kiafya. Fahirisi ya uzito wa mwili (BMI) zaidi ya 25 inachukuliwa kuwa mnene kupita kiasi, na zaidi ya 30 ni feta.1<\/sup> Vituo vya Marekani vya Kudhibiti na Kuzuia Magonjwa vinataja lishe duni na viwango vya chini vya mazoezi ya mwili kuwa sababu za hatari kwa kunenepa kupita kiasi, zinazoathiri takriban 42% ya watu wazima na 20% ya watoto.2<\/sup><\/p>\n

Kuenea kwa ugonjwa wa kunona kupita kiasi kunaongezeka katika sehemu za idadi ya watu na maeneo ya ulimwengu ambayo haijawahi kuwa wasiwasi hapo awali, ikijumuisha ongezeko mara nne la viwango vya unene kwa watoto tangu katikati ya miaka ya 1970.1<\/sup> Mbinu ya sasa ya kupunguza uzito na watoa huduma za matibabu inalenga awali katika kutibu sababu za msingi na kisha kuboresha vipengele vya maisha kama vile chakula na mazoezi.<\/p>\n

Chaguzi za upasuaji kwa ajili ya kutibu fetma zimekuwepo kwa miongo kadhaa (kwa mfano. Gastric bypass, gastric sleeve). Katika miaka ya hivi karibuni, tasnia ya dawa imeanzisha idadi ya dawa ambazo zimethibitishwa kuwa bora katika kupunguza uzito ikilinganishwa na placebo. Kuna vipokezi viwili vya glucagon-kama peptide-1 (GLP-1) ambavyo vimeidhinishwa kwa matibabu ya unene uliokithiri nchini Marekani: semaglutide na liraglutide. Dawa hizi zote mbili ni za sindano. Majina ya chapa ya semaglutide ni pamoja na: Ozempic, Rybelsus, na Wegovy. Majina ya chapa ya liraglutide ni pamoja na: Saxenda na Victoza.<\/p>\n

Dawa hizi hufanya kazi kwa kuruhusu mwili wako kutumia insulini kwa ufanisi zaidi, kupunguza kasi ya digestion yako, na kwa kutenda kwenye maeneo ya ubongo yanayohusika katika kudhibiti hamu yako.3<\/sup> Insulini ni homoni inayoruhusu seli zako kutumia glukosi kutoka kwenye chakula chako. Utambuzi mmoja unaohusishwa na fetma ni ugonjwa wa kisukari cha aina ya 2. Katika aina ya 2 ya kisukari, mwili wako unakuwa na uwezo mdogo wa kutengeneza insulini na kutoitikia insulini inayoitengeneza. Hii inafanya kuwa vigumu kwa seli zote za mwili wako kufanya kazi vizuri. Wagonjwa wa GLP-1 wanaweza kutumika kama chaguo la matibabu kwa ugonjwa wa kisukari cha aina ya 2 kwa wagonjwa fulani.<\/p>\n

Madhara ya kawaida kutoka kwa agonists ya GLP-1 ni pamoja na maumivu ya tumbo, kuvimbiwa, kichefuchefu, kutapika, na kuhara. Kupungua kwa mmeng'enyo wa chakula unaosababishwa na dawa hizi pia hujulikana kama kuchelewa kutoa tumbo. Kuchelewa kutoa tumbo husababisha watu kuhisi kushiba baada ya kila mlo kwa muda mrefu.3<\/sup> Kichefuchefu kinaweza kutokea ukijaribu kula huku ukiwa umeshiba. GLP-1agonists haipaswi kutumiwa kwa watu walio na historia ya kongosho, watu walio na ugonjwa wa kisukari cha aina ya 1, na wale ambao ni wajawazito au wanaopanga kupata mimba.<\/p>\n

Wagonjwa wa GLP-1 hawakusudiwa kuagizwa kwa kila mtu. Watu wanaohitimu kupata dawa hii kama matibabu ya kudhibiti uzito lazima wawe na BMI ya zaidi ya au sawa na 30. Vinginevyo, wagonjwa ambao wana BMI kubwa kuliko au sawa na 27 NA hali nyingine ya matibabu kutokana na uzito kupita kiasi (kwa mfano, shinikizo la damu). , cholesterol ya juu) itastahili.<\/p>\n

Mchanganyiko wa marekebisho ya mtindo wa maisha na dawa za kupunguza unene umeonyesha ufanisi katika majaribio ya kimatibabu.4,5<\/sup> Mwitikio kwa agonists wa GLP-1 hutofautiana sana kati ya wagonjwa. Watu wanahitaji kufanya kazi kwa karibu na mtoa huduma ya afya ili kupata kipimo bora cha dawa ambacho kinawafaa. Sio tu utahitaji kuwa na uzito wako kufuatiliwa kwa karibu, lakini watoa huduma wengi wanaweza pia kufuatilia shinikizo la damu yako na kiwango cha moyo mara kwa mara. Iwapo hutapunguza 4-5% ya uzito wa mwili wako baada ya miezi 3 ya dawa kwa kiwango cha juu zaidi kinachostahimili, mtoa huduma wako wa afya anaweza kukusaidia katika kusimamisha dawa polepole. Kwa sasa hakuna miongozo iliyo wazi ya kujaribu agonists mbadala wa GLP-1 au matibabu mengine ya dawa ikiwa dawa ya awali haikufanya kazi. Uamuzi wa kujaribu matibabu mengine utakuwa kwa kila mgonjwa binafsi na mtoa huduma.<\/p>\n

Kwa wakati fulani, watu wataacha kupoteza uzito wakati wa kutumia dawa hizi na wanaweza kuhitaji mikakati ya ziada ya kupoteza uzito zaidi. Kuongezeka kwa uzito kunaweza kutarajiwa wakati dawa hizi zimesimamishwa. Uzito huu hutokea kwa sababu miili yetu hufanya kazi kwa bidii ili kudumisha uzito wao unaopendelea. Uwezo wetu wa msingi wa kuchoma kalori utapungua kwa kupoteza uzito6<\/sup> na homoni zinazotuambia tuna njaa zitaingia kwenye gari kupita kiasi ili kurudi kwenye kiwango chetu cha ndani.7<\/sup> Wanasayansi wanaendelea kujifunza madhara ya muda mrefu ya kupoteza uzito kwenye kimetaboliki na homoni zetu kwa sababu watu wengi hupata uzito uliopotea ndani ya miaka 2-3.8<\/sup> Kwa hivyo, ikiwa kupoteza uzito kunapatikana kwa ufanisi na agonist ya GLP-1, kuendelea nao kwa muda mrefu kunaweza kuwa muhimu ili kudumisha faida.<\/p>\n

Je, dawa hizi ni sawa kwako? Utahitaji kushauriana na mtoa huduma wako wa afya ili kubaini kama unastahili kupata dawa hizi na kama zinafaa kwako.<\/p>\n

Kazi Zilizotajwa:<\/p>\n

1. Unene kupita kiasi (who.int)<\/a>
2. HOP 2023 | NOFO | DNPAO | CDC<\/a>
3. Glucagon-Kama Peptide-1 Receptor Agonists - StatPearls - NCBI Bookshelf (nih.gov)<\/a>
4. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Chama cha Matibabu ya Kifamasia kwa Unene Wenye Kupunguza Uzito na Matukio Mbaya: Mapitio ya Kitaratibu na Uchambuzi wa Meta. JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001\/jama.2016.7602. Erratum katika: JAMA. 2016 Sep 6;316(9):995. PMID: 27299618; PMCID: PMC5617638.<\/a>
5. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT; HATUA YA 8 Wachunguzi. Madhara ya Semaglutide ya Kila Wiki ya Subcutaneous vs Liraglutide ya Kila Siku juu ya Uzito wa Mwili kwa Watu Wazima Wenye Uzito Kubwa au Fetma Bila Kisukari: Jaribio la Kliniki la STEP 8 Nasibu. JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001\/jama.2021.23619. PMID: 35015037; PMCID: PMC8753508.<\/a>
6. Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Kudumu kwa muda mrefu kwa thermogenesis inayoweza kubadilika kwa watu ambao wamedumisha uzani wa mwili uliopunguzwa. Am J Clin Nutr. 2008 Oktoba;88(4):906-12. doi: 10.1093\/ajcn\/88.4.906. PMID: 18842775.<\/a>
7. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Kudumu kwa muda mrefu kwa marekebisho ya homoni kwa kupoteza uzito. N Engl J Med. 2011 Okt 27;365(17):1597-604. doi: 10.1056\/NEJMoa1105816. PMID: 22029981.<\/a>
8. Kudumisha Kupunguza Uzito | Dawa ya Johns Hopkins<\/a><\/p>\n

Chanzo cha matibabu cha kila siku<\/a><\/p>\n

","protected":false},"excerpt":{"rendered":"

<\/div>\n

Kulingana na Shirika la Afya Ulimwenguni (WHO), uzito kupita kiasi na unene kupita kiasi hufafanuliwa kuwa \u201cmrundikano wa mafuta kupita kiasi usio wa kawaida au kupita kiasi unaoleta hatari kiafya. Fahirisi ya uzito wa mwili (BMI) zaidi ya 25 inachukuliwa kuwa mnene kupita kiasi, na zaidi ya 30 ni feta.1<\/sup> Vituo vya Marekani vya Kudhibiti na Kuzuia Magonjwa vinataja lishe duni na viwango vya chini vya mazoezi ya mwili kuwa sababu za hatari kwa kunenepa kupita kiasi, zinazoathiri takriban 42% ya watu wazima na 20% ya watoto.2<\/sup><\/p>\n

Kuenea kwa ugonjwa wa kunona kupita kiasi kunaongezeka katika sehemu za idadi ya watu na maeneo ya ulimwengu ambayo haijawahi kuwa wasiwasi hapo awali, ikijumuisha ongezeko mara nne la viwango vya unene kwa watoto tangu katikati ya miaka ya 1970.1<\/sup> Mbinu ya sasa ya kupunguza uzito na watoa huduma za matibabu inalenga awali katika kutibu sababu za msingi na kisha kuboresha vipengele vya maisha kama vile chakula na mazoezi.<\/p>\n

Chaguzi za upasuaji kwa ajili ya kutibu fetma zimekuwepo kwa miongo kadhaa (kwa mfano. Gastric bypass, gastric sleeve). Katika miaka ya hivi karibuni, tasnia ya dawa imeanzisha idadi ya dawa ambazo zimethibitishwa kuwa bora katika kupunguza uzito ikilinganishwa na placebo. Kuna vipokezi viwili vya glucagon-kama peptide-1 (GLP-1) ambavyo vimeidhinishwa kwa matibabu ya unene uliokithiri nchini Marekani: semaglutide na liraglutide. Dawa hizi zote mbili ni za sindano. Majina ya chapa ya semaglutide ni pamoja na: Ozempic, Rybelsus, na Wegovy. Majina ya chapa ya liraglutide ni pamoja na: Saxenda na Victoza.<\/p>\n

Dawa hizi hufanya kazi kwa kuruhusu mwili wako kutumia insulini kwa ufanisi zaidi, kupunguza kasi ya digestion yako, na kwa kutenda kwenye maeneo ya ubongo yanayohusika katika kudhibiti hamu yako.3<\/sup> Insulini ni homoni inayoruhusu seli zako kutumia glukosi kutoka kwenye chakula chako. Utambuzi mmoja unaohusishwa na fetma ni ugonjwa wa kisukari cha aina ya 2. Katika aina ya 2 ya kisukari, mwili wako unakuwa na uwezo mdogo wa kutengeneza insulini na kutoitikia insulini inayoitengeneza. Hii inafanya kuwa vigumu kwa seli zote za mwili wako kufanya kazi vizuri. Wagonjwa wa GLP-1 wanaweza kutumika kama chaguo la matibabu kwa ugonjwa wa kisukari cha aina ya 2 kwa wagonjwa fulani.<\/p>\n

Madhara ya kawaida kutoka kwa agonists ya GLP-1 ni pamoja na maumivu ya tumbo, kuvimbiwa, kichefuchefu, kutapika, na kuhara. Kupungua kwa mmeng'enyo wa chakula unaosababishwa na dawa hizi pia hujulikana kama kuchelewa kutoa tumbo. Kuchelewa kutoa tumbo husababisha watu kuhisi kushiba baada ya kila mlo kwa muda mrefu.3<\/sup> Kichefuchefu kinaweza kutokea ukijaribu kula huku ukiwa umeshiba. GLP-1agonists haipaswi kutumiwa kwa watu walio na historia ya kongosho, watu walio na ugonjwa wa kisukari cha aina ya 1, na wale ambao ni wajawazito au wanaopanga kupata mimba.<\/p>\n

Wagonjwa wa GLP-1 hawakusudiwa kuagizwa kwa kila mtu. Watu wanaohitimu kupata dawa hii kama matibabu ya kudhibiti uzito lazima wawe na BMI ya zaidi ya au sawa na 30. Vinginevyo, wagonjwa ambao wana BMI kubwa kuliko au sawa na 27 NA hali nyingine ya matibabu kutokana na uzito kupita kiasi (kwa mfano, shinikizo la damu). , cholesterol ya juu) itastahili.<\/p>\n

Mchanganyiko wa marekebisho ya mtindo wa maisha na dawa za kupunguza unene umeonyesha ufanisi katika majaribio ya kimatibabu.4,5<\/sup> Mwitikio kwa agonists wa GLP-1 hutofautiana sana kati ya wagonjwa. Watu wanahitaji kufanya kazi kwa karibu na mtoa huduma ya afya ili kupata kipimo bora cha dawa ambacho kinawafaa. Sio tu utahitaji kuwa na uzito wako kufuatiliwa kwa karibu, lakini watoa huduma wengi wanaweza pia kufuatilia shinikizo la damu yako na kiwango cha moyo mara kwa mara. Iwapo hutapunguza 4-5% ya uzito wa mwili wako baada ya miezi 3 ya dawa kwa kiwango cha juu zaidi kinachostahimili, mtoa huduma wako wa afya anaweza kukusaidia katika kusimamisha dawa polepole. Kwa sasa hakuna miongozo iliyo wazi ya kujaribu agonists mbadala wa GLP-1 au matibabu mengine ya dawa ikiwa dawa ya awali haikufanya kazi. Uamuzi wa kujaribu matibabu mengine utakuwa kwa kila mgonjwa binafsi na mtoa huduma.<\/p>\n

Kwa wakati fulani, watu wataacha kupoteza uzito wakati wa kutumia dawa hizi na wanaweza kuhitaji mikakati ya ziada ya kupoteza uzito zaidi. Kuongezeka kwa uzito kunaweza kutarajiwa wakati dawa hizi zimesimamishwa. Uzito huu hutokea kwa sababu miili yetu hufanya kazi kwa bidii ili kudumisha uzito wao unaopendelea. Uwezo wetu wa msingi wa kuchoma kalori utapungua kwa kupoteza uzito6<\/sup> na homoni zinazotuambia tuna njaa zitaingia kwenye gari kupita kiasi ili kurudi kwenye kiwango chetu cha ndani.7<\/sup> Wanasayansi wanaendelea kujifunza madhara ya muda mrefu ya kupoteza uzito kwenye kimetaboliki na homoni zetu kwa sababu watu wengi hupata uzito uliopotea ndani ya miaka 2-3.8<\/sup> Kwa hivyo, ikiwa kupoteza uzito kunapatikana kwa ufanisi na agonist ya GLP-1, kuendelea nao kwa muda mrefu kunaweza kuwa muhimu ili kudumisha faida.<\/p>\n

Je, dawa hizi ni sawa kwako? Utahitaji kushauriana na mtoa huduma wako wa afya ili kubaini kama unastahili kupata dawa hizi na kama zinafaa kwako.<\/p>\n

Kazi Zilizotajwa:<\/p>\n

1. Unene kupita kiasi (who.int)<\/a>
2. HOP 2023 | NOFO | DNPAO | CDC<\/a>
3. Glucagon-Kama Peptide-1 Receptor Agonists - StatPearls - NCBI Bookshelf (nih.gov)<\/a>
4. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Chama cha Matibabu ya Kifamasia kwa Unene Wenye Kupunguza Uzito na Matukio Mbaya: Mapitio ya Kitaratibu na Uchambuzi wa Meta. JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001\/jama.2016.7602. Erratum katika: JAMA. 2016 Sep 6;316(9):995. PMID: 27299618; PMCID: PMC5617638.<\/a>
5. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT; HATUA YA 8 Wachunguzi. Madhara ya Semaglutide ya Kila Wiki ya Subcutaneous vs Liraglutide ya Kila Siku juu ya Uzito wa Mwili kwa Watu Wazima Wenye Uzito Kubwa au Fetma Bila Kisukari: Jaribio la Kliniki la STEP 8 Nasibu. JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001\/jama.2021.23619. PMID: 35015037; PMCID: PMC8753508.<\/a>
6. Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Kudumu kwa muda mrefu kwa thermogenesis inayoweza kubadilika kwa watu ambao wamedumisha uzani wa mwili uliopunguzwa. Am J Clin Nutr. 2008 Oktoba;88(4):906-12. doi: 10.1093\/ajcn\/88.4.906. PMID: 18842775.<\/a>
7. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Kudumu kwa muda mrefu kwa marekebisho ya homoni kwa kupoteza uzito. N Engl J Med. 2011 Okt 27;365(17):1597-604. doi: 10.1056\/NEJMoa1105816. PMID: 22029981.<\/a>
8. Kudumisha Kupunguza Uzito | Dawa ya Johns Hopkins<\/a><\/p>","protected":false},"author":2,"featured_media":8790,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"fifu_image_url":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg","fifu_image_alt":"","footnotes":""},"categories":[27],"tags":[],"class_list":["post-8789","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"yoast_head":"\nIs There A Medication That will Eliminate Obesity? - Urban Care Clinic<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/urbancare.clinic\/sw\/kuna-dawa-ambayo-itaondoa-unene\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Is There A Medication That will Eliminate Obesity? - Urban Care Clinic\" \/>\n<meta property=\"og:description\" content=\"According to the World Health Organization (WHO), overweight and obesity are defined as "abnormal or excessive fat accumulation that presents a health risk. A body mass index (BMI) over 25 is considered overweight, and over 30 is obese."1 The United States Centers for Disease Control and Prevention cites poor diet and low physical activity levels as risk factors for obesity, affecting approximately 42% of adults and 20% of children.2The prevalence of obesity is climbing in segments of the population and areas of the world in which it has not previously been a concern, including a fourfold increase in obesity rates in children since the mid-1970's.1 The current approach to weight loss by medical providers focuses initially on treating underlying causes and then on optimizing lifestyle factors such as diet and exercise.Surgical options for treating obesity have been around for decades (eg. Gastric bypass, gastric sleeve). In recent years, the pharmaceutical industry has introduced a number of medications that have been proven effective at reducing weight compared to placebo. There are two glucagon-like peptide-1 (GLP-1) receptor agonists that have been approved for the treatment of obesity in the United States: semaglutide and liraglutide. Both of these medications are injectable. The brand names for semaglutide include: Ozempic, Rybelsus, and Wegovy. The brand names for liraglutide include: Saxenda and Victoza.These medications work by allowing your body to use insulin more effectively, slowing down your digestion, and by acting on areas of the brain involved in managing your appetite.3 Insulin is a hormone that allows your cells to use the glucose from your food. One diagnosis commonly associated with obesity is type 2 Diabetes. In type 2 Diabetes, your body becomes less able to make insulin and less responsive to the insulin it does make. This makes it difficult for all your body's cells to function properly. The GLP-1 agonists can be used as a treatment option for type 2 Diabetes in certain patients.The most common side effects from GLP-1 agonists include abdominal pain, constipation, nausea, vomiting, and diarrhea. The slowed digestion caused by these medications is also known as delayed gastric emptying. Delayed gastric emptying leads to people feeling fuller after each meal for longer.3 Nausea can result if you attempt to eat while feeling full. GLP-1agonists should not be used in people with a history of pancreatitis, people with type 1 diabetes, and those who are pregnant or planning to become pregnant.GLP-1 agonists are not meant to be prescribed for everyone. People who qualify for this medication as a weight management treatment must have a BMI of greater than or equal to 30. Alternatively, patients who have a BMI greater than or equal to 27 AND another medical condition due to being overweight (eg. High blood pressure, high cholesterol) will qualify.A combination of lifestyle modifications and anti-obesity medications has shown efficacy in clinical trials.4,5 The response to GLP-1 agonists varies widely between patients. People need to work closely with a healthcare provider to find the optimal dose of the medication that is right for them. Not only will you need to have your weight closely monitored, but many providers will likely also monitor your blood pressure and heart rate regularly. If you do not lose 4-5% of your body weight after 3 months of medication at the highest tolerated dose, your healthcare provider will likely assist you in slowly stopping the medication. There are not currently clear guidelines for trying alternative GLP-1 agonists or other medication therapies if the initial medication did not work. The decision to trial other therapies will be up to each individual patient and provider.At a certain point, people will stop losing weight while on these medications and may need additional strategies for more weight loss. Weight gain can be expected when these medications are stopped. This weight gain occurs because our bodies work very hard to maintain their preferred weight. Our baseline ability to burn calories will decrease with weight loss6 and the hormones that tell us we are hungry will go into overdrive to return to our internal set point.7 Scientists continue to study the long-term effects of weight loss on our metabolism and hormones because most people regain lost weight within 2-3 years.8 Therefore, if weight loss is successfully achieved with a GLP-1 agonist, continuing them longer term may be necessary to maintain the benefits.Are these medications right for you? You will need to consult your healthcare provider to determine if you qualify for these medications and if they are right for you.Works Cited:1. Obesity (who.int)2. HOP 2023 | NOFO | DNPAO | CDC3. Glucagon-Like Peptide-1 Receptor Agonists - StatPearls - NCBI Bookshelf (nih.gov)4. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001\/jama.2016.7602. Erratum in: JAMA. 2016 Sep 6;316(9):995. PMID: 27299618; PMCID: PMC5617638.5. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001\/jama.2021.23619. PMID: 35015037; PMCID: PMC8753508.6. Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr. 2008 Oct;88(4):906-12. doi: 10.1093\/ajcn\/88.4.906. PMID: 18842775.7. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011 Oct 27;365(17):1597-604. doi: 10.1056\/NEJMoa1105816. PMID: 22029981.8. Maintaining Weight Loss | Johns Hopkins Medicine\" \/>\n<meta property=\"og:url\" content=\"https:\/\/urbancare.clinic\/sw\/kuna-dawa-ambayo-itaondoa-unene\/\" \/>\n<meta property=\"og:site_name\" content=\"Urban Care Clinic\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/urbancarezanzibar\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-30T14:07:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg\" \/>\n<meta name=\"author\" content=\"Urban Care Clinic\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Urban Care Clinic\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"dakika 5\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/\"},\"author\":{\"name\":\"Urban Care Clinic\",\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/person\/f286c4d84be896d302aceda3ed7e789c\"},\"headline\":\"Is There A Medication That will Eliminate Obesity?\",\"datePublished\":\"2023-10-30T14:07:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/\"},\"wordCount\":948,\"publisher\":{\"@id\":\"https:\/\/urbancare.clinic\/#organization\"},\"image\":{\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg\",\"articleSection\":[\"Medical Daily\"],\"inLanguage\":\"sw\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/\",\"url\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/\",\"name\":\"Is There A Medication That will Eliminate Obesity? - Urban Care Clinic\",\"isPartOf\":{\"@id\":\"https:\/\/urbancare.clinic\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg\",\"datePublished\":\"2023-10-30T14:07:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#breadcrumb\"},\"inLanguage\":\"sw\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"sw\",\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage\",\"url\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg\",\"contentUrl\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg\",\"caption\":\"Is There A Medication That will Eliminate Obesity?\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/urbancare.clinic\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Is There A Medication That will Eliminate Obesity?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/urbancare.clinic\/#website\",\"url\":\"https:\/\/urbancare.clinic\/\",\"name\":\"Urban Care Clinic\",\"description\":\"Your Medical Healthcare Clinic in Zanzibar\",\"publisher\":{\"@id\":\"https:\/\/urbancare.clinic\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/urbancare.clinic\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sw\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/urbancare.clinic\/#organization\",\"name\":\"Urban Care Clinic Zanzibar\",\"alternateName\":\"Urban Care Clinic\",\"url\":\"https:\/\/urbancare.clinic\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sw\",\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2022\/07\/Urban-Care-Clinic-Logo-Trans-512x512-1.png\",\"contentUrl\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2022\/07\/Urban-Care-Clinic-Logo-Trans-512x512-1.png\",\"width\":500,\"height\":500,\"caption\":\"Urban Care Clinic Zanzibar\"},\"image\":{\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/urbancarezanzibar\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/person\/f286c4d84be896d302aceda3ed7e789c\",\"name\":\"Urban Care Clinic\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sw\",\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/8f8b5f9c42679ce61ae24fd31561a4574502595c4b3428a4fdf92d929bf09352?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/8f8b5f9c42679ce61ae24fd31561a4574502595c4b3428a4fdf92d929bf09352?s=96&d=mm&r=g\",\"caption\":\"Urban Care Clinic\"},\"url\":\"https:\/\/urbancare.clinic\/sw\/author\/urban-care-clinic\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Je, Kuna Dawa Ya Kuondoa Unene? - Kliniki ya Huduma ya Mjini","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/urbancare.clinic\/sw\/kuna-dawa-ambayo-itaondoa-unene\/","og_locale":"en_US","og_type":"article","og_title":"Is There A Medication That will Eliminate Obesity? - Urban Care Clinic","og_description":"According to the World Health Organization (WHO), overweight and obesity are defined as \"abnormal or excessive fat accumulation that presents a health risk. A body mass index (BMI) over 25 is considered overweight, and over 30 is obese.\"1 The United States Centers for Disease Control and Prevention cites poor diet and low physical activity levels as risk factors for obesity, affecting approximately 42% of adults and 20% of children.2The prevalence of obesity is climbing in segments of the population and areas of the world in which it has not previously been a concern, including a fourfold increase in obesity rates in children since the mid-1970's.1 The current approach to weight loss by medical providers focuses initially on treating underlying causes and then on optimizing lifestyle factors such as diet and exercise.Surgical options for treating obesity have been around for decades (eg. Gastric bypass, gastric sleeve). In recent years, the pharmaceutical industry has introduced a number of medications that have been proven effective at reducing weight compared to placebo. There are two glucagon-like peptide-1 (GLP-1) receptor agonists that have been approved for the treatment of obesity in the United States: semaglutide and liraglutide. Both of these medications are injectable. The brand names for semaglutide include: Ozempic, Rybelsus, and Wegovy. The brand names for liraglutide include: Saxenda and Victoza.These medications work by allowing your body to use insulin more effectively, slowing down your digestion, and by acting on areas of the brain involved in managing your appetite.3 Insulin is a hormone that allows your cells to use the glucose from your food. One diagnosis commonly associated with obesity is type 2 Diabetes. In type 2 Diabetes, your body becomes less able to make insulin and less responsive to the insulin it does make. This makes it difficult for all your body's cells to function properly. The GLP-1 agonists can be used as a treatment option for type 2 Diabetes in certain patients.The most common side effects from GLP-1 agonists include abdominal pain, constipation, nausea, vomiting, and diarrhea. The slowed digestion caused by these medications is also known as delayed gastric emptying. Delayed gastric emptying leads to people feeling fuller after each meal for longer.3 Nausea can result if you attempt to eat while feeling full. GLP-1agonists should not be used in people with a history of pancreatitis, people with type 1 diabetes, and those who are pregnant or planning to become pregnant.GLP-1 agonists are not meant to be prescribed for everyone. People who qualify for this medication as a weight management treatment must have a BMI of greater than or equal to 30. Alternatively, patients who have a BMI greater than or equal to 27 AND another medical condition due to being overweight (eg. High blood pressure, high cholesterol) will qualify.A combination of lifestyle modifications and anti-obesity medications has shown efficacy in clinical trials.4,5 The response to GLP-1 agonists varies widely between patients. People need to work closely with a healthcare provider to find the optimal dose of the medication that is right for them. Not only will you need to have your weight closely monitored, but many providers will likely also monitor your blood pressure and heart rate regularly. If you do not lose 4-5% of your body weight after 3 months of medication at the highest tolerated dose, your healthcare provider will likely assist you in slowly stopping the medication. There are not currently clear guidelines for trying alternative GLP-1 agonists or other medication therapies if the initial medication did not work. The decision to trial other therapies will be up to each individual patient and provider.At a certain point, people will stop losing weight while on these medications and may need additional strategies for more weight loss. Weight gain can be expected when these medications are stopped. This weight gain occurs because our bodies work very hard to maintain their preferred weight. Our baseline ability to burn calories will decrease with weight loss6 and the hormones that tell us we are hungry will go into overdrive to return to our internal set point.7 Scientists continue to study the long-term effects of weight loss on our metabolism and hormones because most people regain lost weight within 2-3 years.8 Therefore, if weight loss is successfully achieved with a GLP-1 agonist, continuing them longer term may be necessary to maintain the benefits.Are these medications right for you? You will need to consult your healthcare provider to determine if you qualify for these medications and if they are right for you.Works Cited:1. Obesity (who.int)2. HOP 2023 | NOFO | DNPAO | CDC3. Glucagon-Like Peptide-1 Receptor Agonists - StatPearls - NCBI Bookshelf (nih.gov)4. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001\/jama.2016.7602. Erratum in: JAMA. 2016 Sep 6;316(9):995. PMID: 27299618; PMCID: PMC5617638.5. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001\/jama.2021.23619. PMID: 35015037; PMCID: PMC8753508.6. Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr. 2008 Oct;88(4):906-12. doi: 10.1093\/ajcn\/88.4.906. PMID: 18842775.7. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011 Oct 27;365(17):1597-604. doi: 10.1056\/NEJMoa1105816. PMID: 22029981.8. Maintaining Weight Loss | Johns Hopkins Medicine","og_url":"https:\/\/urbancare.clinic\/sw\/kuna-dawa-ambayo-itaondoa-unene\/","og_site_name":"Urban Care Clinic","article_publisher":"https:\/\/www.facebook.com\/urbancarezanzibar","article_published_time":"2023-10-30T14:07:28+00:00","og_image":[{"url":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg","type":"","width":"","height":""}],"author":"Urban Care Clinic","twitter_card":"summary_large_image","twitter_image":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg","twitter_misc":{"Written by":"Urban Care Clinic","Est. reading time":"dakika 5"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#article","isPartOf":{"@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/"},"author":{"name":"Urban Care Clinic","@id":"https:\/\/urbancare.clinic\/#\/schema\/person\/f286c4d84be896d302aceda3ed7e789c"},"headline":"Is There A Medication That will Eliminate Obesity?","datePublished":"2023-10-30T14:07:28+00:00","mainEntityOfPage":{"@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/"},"wordCount":948,"publisher":{"@id":"https:\/\/urbancare.clinic\/#organization"},"image":{"@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage"},"thumbnailUrl":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg","articleSection":["Medical Daily"],"inLanguage":"sw"},{"@type":"WebPage","@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/","url":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/","name":"Je, Kuna Dawa Ya Kuondoa Unene? - Kliniki ya Huduma ya Mjini","isPartOf":{"@id":"https:\/\/urbancare.clinic\/#website"},"primaryImageOfPage":{"@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage"},"image":{"@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage"},"thumbnailUrl":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg","datePublished":"2023-10-30T14:07:28+00:00","breadcrumb":{"@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#breadcrumb"},"inLanguage":"sw","potentialAction":[{"@type":"ReadAction","target":["https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/"]}]},{"@type":"ImageObject","inLanguage":"sw","@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage","url":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg","contentUrl":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg","caption":"Is There A Medication That will Eliminate Obesity?"},{"@type":"BreadcrumbList","@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/urbancare.clinic\/"},{"@type":"ListItem","position":2,"name":"Is There A Medication That will Eliminate Obesity?"}]},{"@type":"WebSite","@id":"https:\/\/urbancare.clinic\/#website","url":"https:\/\/urbancare.clinic\/","name":"Kliniki ya Huduma ya Mjini","description":"Kliniki yako ya Afya Zanzibar","publisher":{"@id":"https:\/\/urbancare.clinic\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/urbancare.clinic\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sw"},{"@type":"Organization","@id":"https:\/\/urbancare.clinic\/#organization","name":"Kliniki ya Huduma ya Mijini Zanzibar","alternateName":"Urban Care Clinic","url":"https:\/\/urbancare.clinic\/","logo":{"@type":"ImageObject","inLanguage":"sw","@id":"https:\/\/urbancare.clinic\/#\/schema\/logo\/image\/","url":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2022\/07\/Urban-Care-Clinic-Logo-Trans-512x512-1.png","contentUrl":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2022\/07\/Urban-Care-Clinic-Logo-Trans-512x512-1.png","width":500,"height":500,"caption":"Urban Care Clinic Zanzibar"},"image":{"@id":"https:\/\/urbancare.clinic\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/urbancarezanzibar"]},{"@type":"Person","@id":"https:\/\/urbancare.clinic\/#\/schema\/person\/f286c4d84be896d302aceda3ed7e789c","name":"Kliniki ya Huduma ya Mjini","image":{"@type":"ImageObject","inLanguage":"sw","@id":"https:\/\/urbancare.clinic\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/8f8b5f9c42679ce61ae24fd31561a4574502595c4b3428a4fdf92d929bf09352?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8f8b5f9c42679ce61ae24fd31561a4574502595c4b3428a4fdf92d929bf09352?s=96&d=mm&r=g","caption":"Urban Care Clinic"},"url":"https:\/\/urbancare.clinic\/sw\/author\/urban-care-clinic\/"}]}},"_links":{"self":[{"href":"https:\/\/urbancare.clinic\/sw\/wp-json\/wp\/v2\/posts\/8789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/urbancare.clinic\/sw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/urbancare.clinic\/sw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/urbancare.clinic\/sw\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/urbancare.clinic\/sw\/wp-json\/wp\/v2\/comments?post=8789"}],"version-history":[{"count":0,"href":"https:\/\/urbancare.clinic\/sw\/wp-json\/wp\/v2\/posts\/8789\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/urbancare.clinic\/sw\/wp-json\/wp\/v2\/media\/8790"}],"wp:attachment":[{"href":"https:\/\/urbancare.clinic\/sw\/wp-json\/wp\/v2\/media?parent=8789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/urbancare.clinic\/sw\/wp-json\/wp\/v2\/categories?post=8789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/urbancare.clinic\/sw\/wp-json\/wp\/v2\/tags?post=8789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}